Minerva Neurosciences Stock Forecast, Price & News

-0.04 (-1.49 %)
(As of 06/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume809 shs
Average Volume1.16 million shs
Market Capitalization$112.79 million
P/E Ratio16.50
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive NERV News and Ratings via Email

Sign-up to receive the latest news and ratings for Minerva Neurosciences and its competitors with MarketBeat's FREE daily newsletter.

Minerva Neurosciences logo

About Minerva Neurosciences

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, a compound in Phase III clinical trial for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.81 out of 5 stars

Medical Sector

196th out of 2,100 stocks

Pharmaceutical Preparations Industry

88th out of 831 stocks

Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Minerva Neurosciences (NASDAQ:NERV) Frequently Asked Questions

Is Minerva Neurosciences a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Minerva Neurosciences stock.
View analyst ratings for Minerva Neurosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Minerva Neurosciences?

Wall Street analysts have given Minerva Neurosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Minerva Neurosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Minerva Neurosciences?

Minerva Neurosciences saw a drop in short interest in the month of May. As of May 28th, there was short interest totaling 3,350,000 shares, a drop of 34.7% from the May 13th total of 5,130,000 shares. Based on an average trading volume of 1,470,000 shares, the days-to-cover ratio is presently 2.3 days. Approximately 8.1% of the company's stock are short sold.
View Minerva Neurosciences' Short Interest

When is Minerva Neurosciences' next earnings date?

Minerva Neurosciences is scheduled to release its next quarterly earnings announcement on Monday, August 2nd 2021.
View our earnings forecast for Minerva Neurosciences

How were Minerva Neurosciences' earnings last quarter?

Minerva Neurosciences, Inc. (NASDAQ:NERV) released its quarterly earnings results on Wednesday, May, 12th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.20 by $0.41.
View Minerva Neurosciences' earnings history

How has Minerva Neurosciences' stock been impacted by COVID-19 (Coronavirus)?

Minerva Neurosciences' stock was trading at $6.36 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NERV stock has decreased by 58.5% and is now trading at $2.64.
View which stocks have been most impacted by COVID-19

What price target have analysts set for NERV?

3 brokers have issued 1-year target prices for Minerva Neurosciences' shares. Their forecasts range from $9.00 to $10.00. On average, they anticipate Minerva Neurosciences' stock price to reach $9.50 in the next year. This suggests a possible upside of 259.8% from the stock's current price.
View analysts' price targets for Minerva Neurosciences
or view top-rated stocks among Wall Street analysts.

Who are Minerva Neurosciences' key executives?

Minerva Neurosciences' management team includes the following people:
  • Dr. Remy Luthringer Ph.D., Exec. Chairman & CEO (Age 60, Pay $850.3k)
  • Mr. Geoffrey Robin Race, Exec. VP, CFO & Chief Bus. Officer (Age 60, Pay $644.2k)
  • Dr. Jay B. Saoud Ph.D., Sr. VP and Head of R&D (Age 62, Pay $613.84k)
  • Mr. Joseph Reilly, Sr. VP & COO (Age 46)
  • Mr. Frederick W. Ahlholm, Sr. VP & Chief Accounting Officer (Age 55)
  • Mr. William B. Boni, VP of Investor Relations & Corp. Communications (Age 69)
  • Mr. Devin Whittemore Smith, Sr. VP, Gen. Counsel & Sec. (Age 53)
  • Dr. Michael Davidson, Chief Medical Officer (Age 71)

Who are some of Minerva Neurosciences' key competitors?

What other stocks do shareholders of Minerva Neurosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Minerva Neurosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), PTC Therapeutics (PTCT), Immunomedics (IMMU), VBI Vaccines (VBIV), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Moderna (MRNA), T2 Biosystems (TTOO) and Advanced Micro Devices (AMD).

What is Minerva Neurosciences' stock symbol?

Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."

Who are Minerva Neurosciences' major shareholders?

Minerva Neurosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.46%), Acadian Asset Management LLC (4.08%), Dimensional Fund Advisors LP (2.55%), Goldman Sachs Group Inc. (2.24%), Morgan Stanley (2.17%) and Armistice Capital LLC (2.13%). Company insiders that own Minerva Neurosciences stock include David Kupfer, Frederick W Ahlholm, Geoff Race, Heek G Jan Van, Joseph H Reilly, Remy Luthringer and Venture Associates L Index III.
View institutional ownership trends for Minerva Neurosciences

Which institutional investors are selling Minerva Neurosciences stock?

NERV stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Russell Investments Group Ltd., Dimensional Fund Advisors LP, Walleye Capital LLC, Goldman Sachs Group Inc., AQR Capital Management LLC, Northern Trust Corp, and Alliancebernstein L.P.. Company insiders that have sold Minerva Neurosciences company stock in the last year include Frederick W Ahlholm, Geoff Race, Joseph H Reilly, and Remy Luthringer.
View insider buying and selling activity for Minerva Neurosciences
or view top insider-selling stocks.

Which institutional investors are buying Minerva Neurosciences stock?

NERV stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Assenagon Asset Management S.A., Armistice Capital LLC, Los Angeles Capital Management LLC, Millennium Management LLC, BlackRock Inc., Geode Capital Management LLC, and Price T Rowe Associates Inc. MD. Company insiders that have bought Minerva Neurosciences stock in the last two years include David Kupfer, and Heek G Jan Van.
View insider buying and selling activity for Minerva Neurosciences
or or view top insider-buying stocks.

How do I buy shares of Minerva Neurosciences?

Shares of NERV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Minerva Neurosciences' stock price today?

One share of NERV stock can currently be purchased for approximately $2.64.

How much money does Minerva Neurosciences make?

Minerva Neurosciences has a market capitalization of $112.79 million and generates $41.18 million in revenue each year. The biopharmaceutical company earns $1.94 million in net income (profit) each year or $0.05 on an earnings per share basis.

How many employees does Minerva Neurosciences have?

Minerva Neurosciences employs 11 workers across the globe.

What is Minerva Neurosciences' official website?

The official website for Minerva Neurosciences is

Where are Minerva Neurosciences' headquarters?

Minerva Neurosciences is headquartered at 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451.

How can I contact Minerva Neurosciences?

Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-600-7373 or via email at [email protected]

This page was last updated on 6/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.